Zacks Small-Cap Research

September 18, 2014
Grant Zeng, CFA
312-265-9466
gzeng@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

# Pure Bioscience, Inc. (PURE-OTC)

**PURE:** Strong revenue growth is expected in fiscal 4Q14 and beyond, a reborn company with new focus on food safety—Outperform

| | |
|---|---|
| **Current Recommendation** | **Outperform** |
| Prior Recommendation | Neutral |
| Date of Last Change | 10/16/2013 |
| Current Price (09/17/14) | $1.03 |
| **Twelve- Month Target Price** | **$3.00** |

## OUTLOOK

PURE develops and markets SDC-based antimicrobial products that provide non-toxic solutions to numerous global health challenges. SDC is a novel, patented platform technology with superior efficacy and low toxicity and can be used in diverse markets including food safety, personal care, preservatives, industrials, agriculture and pharmaceuticals.

After recent massive management change, PURE is refocusing on the food safety industry. We expect growth will accelerate in calendar 2H14. We maintain Outperform rating for PURE shares.

## SUMMARY DATA

| | |
|---|---|
| **52-Week High** | **$1.65** |
| **52-Week Low** | **$0.81** |
| **One-Year Return (%)** | **12.22** |
| **Beta** | **0.78** |
| **Average Daily Volume (sh)** | **47,152** |
| **Shares Outstanding (mil)** | **29** |
| **Market Capitalization ($mil)** | **$29** |
| **Short Interest Ratio (days)** | **3.92** |
| **Institutional Ownership (%)** | **9** |
| **Insider Ownership (%)** | **13** |
| **Annual Cash Dividend** | **$0.00** |
| **Dividend Yield (%)** | **0.00** |
| **5-Yr. Historical Growth Rates** | |
| **Sales (%)** | **36.6** |
| **Earnings Per Share (%)** | **N/A** |
| **Dividend (%)** | **N/A** |
| **P/E using TTM EPS** | **N/A** |
| **P/E using 2011 Estimate** | **N/A** |
| **P/E using 2012 Estimate** | **N/A** |
| **Zacks Rank** | **N/A** |

| | |
|---|---|
| **Risk Level** | **High,** |
| **Type of Stock** | **Small-Growth** |
| **Industry** | **Med Products** |
| **Zacks Rank in Industry** | **N/A** |

## ZACKS ESTIMATES

**Revenue**
(in millions of $)

| | Q1 (Oct) | Q2 (Jan) | Q3 (Apr) | Q4 (Jul) | Year (Jul) |
|---|---|---|---|---|---|
| 2013 | 0.11 A | 0.26 A | 0.26 A | 0.19 A | 0.82 A |
| 2014 | 0.12 A | 0.04 A | 0.26 A | 0.36 E | 0.78 E |
| 2015 | | | | | 5.00 E |
| 2016 | | | | | 12.00 E |

**Earnings per Share**
(EPS is operating earnings before non recurring items)

| | Q1 (Oct) | Q2 (Jan) | Q3 (Apr) | Q4 (Jul) | Year (Jul) |
|---|---|---|---|---|---|
| 2013 | -$0.25 A | -$0.17 A | -$0.14 A | -$0.17 A | -$0.71 A |
| 2014 | -$0.06 A | -$0.03 A | -$0.07 A | -$0.07 E | -$0.23 E |
| 2015 | | | | | -$0.09 E |
| 2016 | | | | | $0.02 E |

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

© Copyright 2014, Zacks Investment Research. All Rights Reserved.

## WHAT'S NEW

- Out-license will generate additional revenue for PURE;
- PURE expects to commercialize SDC for use in poultry processing;
- Strong revenue growth expected in fiscal 4Q14 and beyond;
- Maintain Outperform rating and reiterate our 12-month target price of $3.00;

### *Out-Licensing Will Generate Additional Revenue for PURE*

On August 19, 2014, PURE Bioscience announced that, it has entered into a license and distribution agreement with UK-based Research Instruments Limited.

As part of PURE's strategy to out-license **non-food-safety-related markets** for SDC, the agreement provides for the limited exclusive, worldwide, use of an SDC-based surface disinfectant in the niche field of human and animal **in-vitro fertilization**. SDC will be used to disinfect other non-invasive medical devices and instruments used in assisted reproduction facilities.

Research Instruments has completed extensive testing of PURE's SDC-based products as a unique and novel disinfectant, safe for use in the fertility market.

Research Instruments obtained EU marketing approval under EU Medical Device Directive 93/42/EEC and will market the SDC-based technology under its private label Fertisafe Plus™.

The agreement will generate additional revenue for PURE outside the food safety arena. It also serves as an important medical device technology endorsement of SDC.

### *PURE Expects to Launch SDC for use in Poultry Processing in 1Q15*

On July 14, 2014, PURE announced that it has submitted a Food Contact Notification (FCN) to the U.S. FDA for Silver Dihydrogen Citrate (SDC) as an online reprocessing (OLR) antimicrobial for raw poultry processing.

Previously reported test results demonstrated materially significant reduction in Salmonella contamination in poultry.

The FCN review period is 120 days, after which, if there are no concerns from the FDA, the FCN automatically becomes effective. An FCN is considered to be proprietary as it applies only to the specific product and manufacturer or supplier identified in the FCN. Upon the FDA's granting of the FCN, will immediately submit the FCN to the Food Safety and Inspection Service (FSIS) of the USDA for a new technology review.

As part of the FSIS review process, PURE will conduct three in-plant process validation and optimization trials with the authorization of the USDA. After completion of the three in-plant validation trials, PURE expects the USDA to issue a "Letter of No Objection" and list SDC as an OLR poultry processing aid in Attachment 1 of FSIS Directive 7120.1, Safe and Suitable Ingredients Used in the Production of Meat and Poultry Products.

Subject to receipt of both FDA and USDA approval PURE will begin commercialization of SDC in Q1 2015 for use in poultry processing.

### *We Expect Strong Revenue Growth in Fiscal 4Q14 and Beyond*

Based on strong financial performance in fiscal 3Q14 and recent developments, we expect that strong revenue growth will continue in fiscal 4Q14 and beyond.

We remind investors that PURE recently completed the restructuring, and is reborn as a new company with refocused strategy on food safety. We think the new management team has built significant momentum on its refocused business strategy to commercialize its SDC-based technology as a **food safety solution**.

During the third fiscal quarter 2014, the new management team generated significant momentum in advancing its business strategy to commercialize its SDC-based technology as a food safety solution. PURE extended commercial market test launch of PURE® Hard Surface Disinfectant to over 650 stores with a national brand QSR (quick service restaurant). Customer feedback on both SDC product performance and ease of use are very positive. The phased U.S. national rollout is under development for expected system-wide launch. Rollout plans are in development for wider plant adoption from five national food processors who placed commercial pilot orders.

During third quarter, PURE reported outstanding initial test results for the application of SDC as a direct food contact processing aid for raw poultry. Estimated potential addressable U.S. market opportunity for this new application exceeds $1 billion for poultry, produce and meats.

In July, PURE filed for required regulatory authorization from the FDA and USDA for poultry and will file soon for produce and meats. Approval for U.S. commercial use is expected by end of calendar 2014 for poultry. PURE will begin commercialization of SDC in 1Q15 for use in poultry processing.

In order to further penetrate the market, PURE recently hired **Bridget Tinsley** as Vice President Market Development. Tinsley will be responsible for both expanding the market for SDC as a food contact surface disinfectant and sanitizer and leading the future commercial applications of SDC as a food safety aid in the processing of poultry, meat and produce. Tinsley has nearly fifteen years of food industry and food safety experience with diverse expertise across global food programs, territory sales, account management, and laboratory research and business development.

With new management and new strategy, we believe revenue will continue to grow in fiscal 4Q14 and beyond. Specifically, we estimate revenue in fiscal 4Q14 (ending July 31, 2014) will grow 91% to $0.36 million. Total revenue for fiscal 2015 will reach $5.0 million, representing an increase of 544% over fiscal 2014. Positive EBITDA will be achieved by fiscal 4Q15 (July 31, 2015). PURE will become profitable in fiscal 2016 based on total revenue of $12 million according to our financial model. Earnings per share will reach $0.16 by fiscal 2017.

### *Sales Picked Up Steam in Fiscal 3Q14*

On Jun 10, 2014, PURE Bioscience (PURE) reported financial results for the third fiscal quarter ended April 30, 2014.

Revenues for 3Q14 were $0.26 million, compared with revenues of $0.26 million for the third fiscal quarter of 2013, an increase of 1.2%.

R&D expenses for fiscal 3Q14 were $0.25 million, compared to $0.30 million for fiscal 3Q13.

SG&A expenses for fiscal 3Q14 were $1.34 million, compared to $1.46 million for fiscal 3Q13.

Total operating expenses, excluding share-based compensation, and restructuring costs, for the third fiscal quarter of 2014 and 2013, were $1.7 million, and $1.7 million, respectively.

The net loss for the third fiscal quarter of 2014 was $2.0 million ($0.07 per share), compared with a net loss of $1.6 million ($0.14 per share) in the third fiscal quarter of 2013.

**We think the sales growth in fiscal 3Q14 is encouraging**. Although it just increased 1.2% year over year, it's a huge increase from fiscal second quarter sales of $0.04 million. Third quarter revenue of $0.26 million also beat our estimate of $0.15 million. Although the absolute number is not significant, but it's a good sign that revenue is picking up steam and we believe the momentum will continue for the last fiscal quarter of 2014 and beyond.

### *Balance Sheet Cleaned and Boosted*

As of April 30, 2014, PURE had $416,000 in cash and cash equivalents.

In March 2014, PURE raised $1.3 million from the sale of 1.35 million shares of common stock through private equity placements.

During the fiscal 2Q14, PURE extinguished early a promissory note of $1.125 million in principal and other accrued costs for approximately $500,000, resulting in a gain on extinguishment of debt of $727,000. As a consequence, as of April 30, 2014, the Company has **no long-term debt**.

New management has been working diligently to strengthen PURE's balance sheet since they took office. Specific measures included raising new funds and reducing non-core operating activities.

By reducing its non-core operating activities, PURE should be able to reduce its burn rate significantly in the next few quarters.

The process to restore PURE's financial condition will take several steps and we are pleased to see that the company has already made significant strides. We believe the fiscal year 2014 will be both challenging and rewarding as the company sharply focuses on commercializing its patented SDC-based products in the food industry.

### *The Refocused Strategy*

In mid-2013, PURE initiated management change and corporate restructuring in order to establish new and experienced leadership focused on commercialization of SDC technology in the food industry as a unique and proprietary antimicrobial agent to protect consumer safety against various pathogens.

The Company's near-term business focus is to drive customer adoption of its products in the **food safety industry**. Its proprietary SDC-based products uniquely address food safety issues across the supply chain and help to prevent or mitigate food contamination and the potential for food-borne illness. The Company's target customers will be foodservice operators, food processors and food manufacturers.

As part of its new commercialization focus on food safety segment, PURE also strengthened its sales and marketing leadership team. In late August 2013, PURE appointed **Cliff Wechsler** as its new Executive Vice President of Sales, and **Tom Myers** assumed the position of Executive Vice President of Marketing and Product Development.

Mr. Wechsler brings over 30 years of experience, having previously served in a variety of high level sales management positions with Kraft Foods. During his tenure at Kraft Foods Mr. Wechsler shaped and developed the business strategy for their Quick Service Restaurant (QSR) market segment.

Mr. Myers will now lead the company's marketing and product development, having previously joined PURE in May 2011 as Executive Vice President of Sales and Marketing. Mr. Myers brings over 40 years of food industry experience, with emphasis on both food science and food processing where he served in senior leadership positions in marketing, product development and technical operations.

With the new strategy and focus, PURE has reduced costs and personnel in all departments other than sales and marketing as the company continues the push toward meaningful revenues. The company has also established high-capacity outsourcing options for manufacturing to remain positioned to timely fill orders as necessary.

PURE has cut total wage expenditures by more than 30% through the elimination of manufacturing, research and development, administrative and executive positions. The company has also reduced G&A expenses related to professional services, including legal and consulting fees, public relations and investor relations. Furthermore, PURE's corporate officers and directors have elected to defer the majority of cash compensation, effective immediately.

In summary, with the change in governance, PURE Bioscience implemented a new business strategy focused on:

- Commercialization of its SDC-based products as a food safety solution, with a focus on food service and food processing;
- Optimization of operations and termination of non-core activities;
- Implementation of a lean organization with the relevant experience to drive commercialization and accelerate growth;
- Active and experienced board members contributing incremental insight and guidance on business strategy and execution.

***Maintain Our Outperform Rating***

We maintain our Outperform rating on PURE shares and reiterate our 12-month price target of $3.00 per share.

Our call is based on the recent progress the company has achieved and positive developments within the company as well as the attractive valuation.

PURE is a technology-based bioscience company that provides solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity **SDC-based antimicrobials** represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of **"green" products**. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its **superior efficacy**, **reduced toxicity** and the **inability of bacteria to form a resistance** to it.

PURE's SDC is the first new disinfectant registered with EPA in over 30 years. SDC's competitive advantages in efficacy and safety make it outstanding among its competitors and represent a **paradigm shift** in the disinfectant/sanitizer market place.

Another key feature of SDC is that SDC-based products have broad applicability in diverse markets. The Company's current focus is to expand distribution of currently approved **disinfectant/sanitizer** products to consumers in the **food safety industry**.

Recent corporate governance change led to a new management, which is experienced, disciplined and results—oriented. New board will play key incremental role providing strategic insight to accelerate near term market penetration.

In terms of valuation, currently, the Company trades around $1.00 per share with a market cap of $29 million based on 29 million shares outstanding. We think this is a deep discount based on the company's fundamentals. According to our model, revenue will grow at 128% CAGR in the next fiscal 4 years. PURE will become profitable in fiscal 2016 with an EPS of 0.02 based on total revenue of $12.0 million. With this in mind, we think PURE shares should be traded at a P/E ratio of 30 x. Applying this P/E multiple

with our estimated EPS of $0.16 per share in fiscal 2017, discounted at 20% for 3 years, we come up with a target price of $3.00. This values PURE at $87 million in market cap, which we think is still conservative.

But keep in mind the risks. Although its lead product PURE Hard Surface is increasingly gaining recognition, sales may take longer time to gain traction since PURE is still in its early stage of commercialization of its SDC technology. Sales so far have not been impressive. SDC technology is quite new to most customers in the disinfectant market, and the costs for SDC are also higher than those for most existing technologies. Therefore, rollout of the SDC platform will take time.

Cash burn is another concern. Current cash will only last through the fourth quarter of fiscal 2014 and the Company needs to tap the capital market again. Equity financing will dilute existing shareholder base. A financing deal with a strategic partner should be positive to the Company's long term growth.

## COMPANY OVERVIEW

***SDC Represents A Paradigm Shift For Antimicrobial Disinfectant/Sanitizer***

Silver Dihydrogen Citrate (SDC) represents a **paradigm shift** for antimicrobial disinfectant and sanitizer active ingredients. It is the first new active disinfectant ingredient to be registered with the US EPA in over 35 years. SDC is an effective antimicrobial, exhibiting **broad spectrum activity with fast kill times** against bacteria (gram□positive and gram□negative), viruses (enveloped and non□enveloped) and fungi. SDC has a long shelf life and its low toxicity profile does not sacrifice efficacy. It is active against some of the most concerning pathogens in the high density living areas and community settings including MRSA, Norovirus, Influenza, *Acinetobacter*, *Klebsiella*, Vancomycin□resistant *Enterococci*, coliforms (fecal and total), *Legionella*, *E coli* O157:H7, HIV, *Salmonella*, Rotavirus, H1N1, etc.

SDC is used to disinfect and/or sanitize hard, nonporous surfaces. The PURE Hard Surface formulation is a stable, non-toxic, odorless and colorless solution which may be used in the presence of people and animals. This SDC based **Ready to Use** formulation has demonstrated 24 hour residual activity after application to a surface, and requires no rinse after application, saving time and money. And this SDC disinfectant and sanitizer formulation is classified in the US EPA's lowest toxicity category, **Category IV**. A Category IV rating by the US EPA means the Agency considers this formulation relatively non-toxic and they do not require any signal word or precautionary statements on the product label. Compare this to other disinfectants and sanitizers on the market that in their concentrated forms and some in their Ready to Use concentrations are rated as Category I or II with Danger or Warning statements, SDC represents a new generation of microbial control.

**Advantages of SDC** include:

- Powerful broad spectrum protection as a disinfectant, fungicide and virucide
- Faster kill times (kills germs in 30 seconds)
- Provides residual protection for 24 hours
- Effective against resistant bacteria such as MRSA and VRE
- Lowest toxicity rating available
- Labeled for use in diverse environments including restaurants, homes, medical facilities, institutions, day care facilities and on children's toys and play areas
- Does not induce bacterial resistance
- Formulates well with other products
- Stable in solution
- Tasteless, odorless, and colorless

- Non-corrosive, non-flammable
- Doesn't stain or bleach fabric

***Table 1: SDC-based Axen-30 has unparalleled efficacy and low toxicity***

| Unparalleled Efficacy | | |
|---|---|---|
| **Category** | **PURE Hard Surface™** | **Leading Brands** |
| **Active Ingredient** | **Silver dihydrogen citrate** | **Ethanol/Ammonium Chloride** |
| **EPA Safety Category** | IV | II |
| **Standard Bacteria Kill Time** | 30 sec | 10 min |
| **Resistant Bacteria Kill Time** | 2 min | None |
| **Fungal/Virus Kill Time** | 10 min | 10 min |
| **Residual Protection** | 24 hour | None |
| **Rinse Required** | No | Yes |
| **Irritating Fumes** | No | Yes |
| **Skin Irritation** | No | Yes |
| **Flammable** | No | Yes |

***Table 2: SDC's strong efficacy against microbes***

| | MIC of SDC | MBC of SDC |
|---|---|---|
| **Microorganism** | **%SDC (ppm Ag+)** | **%SDC (ppm Ag+)** |
| | | |
| **Corynebacterium xerosis ATCC 373** | 0.12 (2.88 ppm) | |
| **Corynebacterium minutissimum ATCC 23348** | 0.12 (2.88 ppm) | 0.16 (3.84 ppm) |
| **Propionibacterium acnes ATCC 6919** | 0.25 (6.00 ppm) | |
| **Staphylococcus aureus ATCC 6538** | 0.16 (3.84 ppm) | 0.31 (7.44 ppm) |
| **Escherichia coli ATCC 10536** | 0.08 (1.92 ppm) | 0.16 (3.84 ppm) |
| **Pseudomonas aeruginosa ATCC 15442** | 0.16 (3.84 ppm) | 0.08 (1.92 ppm) |
| **Candida albicans ATCC 10231** | 0.12 (2.88 ppm) | >1.25 (30 ppm) |
| **Malassezia furfur DSM 6171** | 0.25 (6.00 ppm) | |
| **Aspergillus niger ATCC 16404** | 0.50 (12 ppm) | >2.5 (60 ppm) |
| **Trichophyton mentagrophytes ATCC 9533** | 0.50 (12 ppm) | 0.08 (1.92 ppm) |
| **Klebsiella pneumonia ATCC 4352** | | 0.16 (3.84 ppm) |
| **Epidermophyton floccosum DSM 10709** | | 0.63 (15.12 ppm) |

*MIC: Minimal Inhibitory Concentrations; MBC: Minimal Bactericidal Concentrations*

*Table 3: SDC has broad spectrum activity with fast kill times*

| Axen 30® EPA Registered Disinfection Claims | |
|---|---|
| **Organism** | **Kill Time** |
| ***Pseudomonas aeruginosa*** | 30 seconds |
| ***Staphylococcus aureus*** | 30 seconds |
| ***Salmonella choleraesuis*** | 30 seconds |
| ***Listeria monocytogenes*** | 30 seconds |
| **Vancomycin resistant *Enterococcus faecium*** | 2 minutes |
| **Methicillin resistant *Staphylococcus aureus (MRSA)*** | 2 minutes |
| ***Escherichia coli* 0157:H7** | 2 minutes |
| ***Trichophyton mentagrophytes* (Athlete's Foot Fungus)** | 10 minutes |
| **HIV type 1- Strain HTLV IIIB** | 30 seconds |
| **Herpes Simplex Type 1 VR-733 F(1) Strain** | 1 minute |
| **Influenza A VR-544, Hong Kong strain** | 10 minutes |
| **Rhinovirus R37 VR-1147, Strain 151-1** | 10 minutes |
| **Human Coronavirus** | 3 minutes |
| **Respiratory Syncytial Virus** | 3 minutes |
| **Adenovirus Type 2** | 3 minutes |
| **Murine Norovirus** | 10 minutes |
| **Norovirus** | 10 minutes |
| **Acinetobacter baumannii** | 2 minutes |
| **Swine Influenza A (H1N1)** | 60 seconds |
| **Influenza A (H1N1)** | 60 seconds |
| **Rotavirus** | 3 minutes |
| **Campylobacter jejuni** | 2 minutes |
| **Community Associated Methicillin resistant Staphylococcus aureus (CA□MRSA□PVL)** | 2 minutes |
| **Community Associated Methicillin resistant Staphylococcus aureus (CA□MRSA)** | 2 minutes |
| **Avian Influenza A** | 10 minutes |
| **Polio Type 2, VR-1002, Lansing Strain** | 10 minutes |

## PROJECTED INCOME STATEMENT

| | 2013A (Jul) | | | | | 2014E (Jul) | | | | | 2015E (Jul) | 2016 (Jul) | 2017 (Jul) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ in million except per share data | Q1A | Q2A | Q3A | Q4A | FYA | Q1A | Q2A | Q3A | Q4E | FYE | FYE | FYE | FYE |
| **Total Revenues** | **$0.11** | **$0.26** | **$0.26** | **$0.19** | **$0.82** | **$0.12** | **$0.04** | **$0.26** | **$0.36** | **$0.78** | **$5.00** | **$12.00** | **$22.00** |
| *YOY Growth* | *-57.2%* | *19.0%* | *24.6%* | *-52.4%* | *-24.2%* | *4.5%* | *-84.4%* | *1.2%* | *90.5%* | *-5.2%* | *543.5%* | *140.0%* | *83.3%* |
| *CoGS* | 0.03 | 0.06 | 0.07 | 0.41 | 0.57 | 0.04 | 0.02 | 0.09 | 0.11 | 0.26 | 1.13 | 2.40 | 4.40 |
| **Gross Income** | **$0.08** | **$0.21** | **$0.19** | **($0.22)** | **$0.26** | **$0.08** | **$0.02** | **$0.17** | **$0.25** | **$0.52** | **$3.88** | **$9.60** | **$17.60** |
| *Gross Margin* | *71.8%* | *78.3%* | *74.0%* | *-116.9%* | *31.1%* | *68.7%* | *51.2%* | *65.9%* | *69.4%* | *67.2%* | *77.5%* | *80.0%* | *80.0%* |
| R&D | $0.40 | $0.41 | $0.30 | $0.22 | $1.33 | $0.23 | $0.29 | $0.25 | $0.30 | $1.07 | $1.10 | $1.40 | $1.55 |
| *% R&D* | *359.1%* | *154.4%* | *117.8%* | *116.4%* | *161.6%* | *203.5%* | *704.9%* | *95.0%* | *83.3%* | *137.8%* | *22.0%* | *11.7%* | *7.0%* |
| SG&A | $1.48 | $1.61 | $1.46 | $1.17 | $5.72 | $0.99 | $1.24 | $1.34 | $1.40 | $4.97 | $5.50 | $7.50 | $9.50 |
| *% SG&A* | *1341.8%* | *612.2%* | *567.4%* | *618.0%* | *697.3%* | *863.5%* | *3031.7%* | *512.6%* | *388.9%* | *640.2%* | *110.0%* | *62.5%* | *43.2%* |
| Other | $0.00 | $0.00 | $0.00 | $0.55 | $0.55 | $2.68 | $1.71 | $0.77 | $0.50 | $5.66 | $0.00 | $0.00 | $0.00 |
| *% Other* | - | - | - | - | - | - | - | - | - | - | - | - | - |
| **Operating Income** | **($1.8)** | **($1.8)** | **($1.6)** | **($2.2)** | **($7.3)** | **($3.8)** | **($3.2)** | **($2.2)** | **($2.0)** | **($11.2)** | **($2.7)** | **$0.7** | **$6.6** |
| *Operating Margin* | - | - | - | - | - | - | - | - | - | - | - | *5.8%* | *29.8%* |
| Other Net | ($0.4) | ($0.0) | $0.0 | $0.0 | ($0.3) | ($0.0) | $0.7 | $0.1 | $0.0 | $0.9 | $0.0 | $0.0 | $0.0 |
| **Pre-Tax Income** | **($2.2)** | **($1.8)** | **($1.6)** | **($2.1)** | **($7.7)** | **($3.8)** | **($2.5)** | **($2.0)** | **($2.0)** | **($10.3)** | **($2.7)** | **$0.7** | **$6.6** |
| Income taxes(benefit) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| *Tax Rate* | - | - | - | - | - | - | - | - | - | - | - | - | - |
| **Reported Net Income** | **($2.2)** | **($1.8)** | **($1.6)** | **($2.1)** | **($7.7)** | **($3.8)** | **($2.5)** | **($2.0)** | **($2.0)** | **($10.3)** | **($2.7)** | **$0.7** | **$6.6** |
| *YOY Growth* | - | - | - | - | - | - | - | - | - | - | - | - | *835.7%* |
| *Net Margin* | - | - | - | - | - | - | - | - | - | - | - | *5.8%* | *29.8%* |
| *Shares Out* | *8.7* | *11.0* | *11.3* | *12.4* | *10.8* | *20.7* | *25.0* | *27.9* | *29.0* | *25.6* | *30.0* | *35.0* | *40.0* |
| **Reported EPS** | **($0.25)** | **($0.17)** | **($0.14)** | **($0.17)** | **($0.71)** | **($0.19)** | **($0.10)** | **($0.07)** | **($0.07)** | **($0.40)** | **($0.09)** | **$0.02** | **$0.16** |
| *YOY Growth* | - | - | - | - | - | - | - | - | - | - | - | | |
| One time charge | *$0.00* | *$0.00* | *$0.00* | *$0.00* | *$0.00* | *$2.68* | *$1.71* | *$0.00* | *$0.00* | *$4.39* | *$0.00* | *$0.00* | *$0.00* |
| **Non GAAP Net Income** | **($2.2)** | **($1.8)** | **($1.6)** | **($2.1)** | **($7.7)** | **($1.2)** | **($0.8)** | **($2.0)** | **($2.0)** | **($5.9)** | **($2.7)** | **$0.7** | **$6.6** |
| **Non GAAP EPS** | **($0.25)** | **($0.17)** | **($0.14)** | **($0.17)** | **($0.71)** | **($0.06)** | **($0.03)** | **($0.07)** | **($0.07)** | **($0.23)** | **($0.09)** | **$0.02** | **$0.16** |

*Source: Company filing and Zacks estimates*

© Copyright 2014, Zacks Investment Research. All Rights Reserved.

## HISTORICAL ZACKS RECOMMENDATIONS




## DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Grant Zeng, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand per annum.

POLICY DISCLOSURES

© Copyright 2014, Zacks Investment Research. All Rights Reserved.

Zacks SCR Analysts are restricted from holding or trading securities in the issuers which they cover. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1068 companies whose securities it covers, including securities covered by Zacks SCR:
Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.
Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.
Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 18.3%, Hold/Neutral- 74.2%, Sell/Underperform – 7.0%. Data is as of midnight on the business day immediately prior to this publication.